Biosimilars

The development of biosimilar medicines has provided an opportunity for patient utilization of oncology treatments at a lower cost, particularly in individuals for whom biologicals play a predominant role in providing effective therapeutic and supportive care. Read More ›

Adoption of biosimilars continues to rise in the United States, but oncologists’ knowledge regarding these agents has not kept pace, according to data presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Quality Care Symposium. Read More ›

The results of a randomized, double-blind phase 3 study established the equivalence of bevacizumab reference to its biosimilar MIL60 in terms of clinical efficacy, safety, population pharmacokinetics, and immunogenicity in patients with nonsquamous NSCLC. Read More ›

The results of a noninterventional, retrospective study showed that rituximab originator and the rituximab-abbs biosimilars yielded comparable efficacy and tolerability in the first-line treatment of patients with CLL and NHL, with rituximab-abbs use resulting in cost-savings. Read More ›

Findings from modeling studies support adjuvant continuation of pertuzumab plus trastuzumab for patients achieving pathologic complete response among patients with high-risk, HER2-positive early breast cancer. Read More ›

Real-world outcomes from a retrospective, single-center study suggested that pegfilgrastim or its biosimilar pegfilgrastim-cbqv does not increase febrile neutropenia or delayed engraftment risk in patients with lymphoma and CLL and may be safe to use after administration of chemotherapy. Read More ›

The results of a retrospective, single-center analysis demonstrated that same-day pegfilgrastim or pegfilgrastim-cbqv was safe and effective in patients with diffuse large B-cell lymphoma who received a rituximab plus miniCHOP chemotherapy regimen, with no significant increase in febrile neutropenia or delayed engraftment. Read More ›

Real-world evidence demonstrated that the characteristics of patients with metastatic colorectal cancer who received bevacizumab-awwb in the first year after product launch were similar regardless of prior bevacizumab use, and that beva­cizumab-awwb was used in new and continuing patients. Read More ›

An observational study indicates that the Oncology Care Model led to reduced use of some high-cost supportive care medications, suggesting the potential for alternative payment models to drive value-based changes in cancer medication use. Read More ›

The findings of a simulation modeling analysis demonstrate that conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb provides significant cost-savings, which could be reallocated on a budget-neutral basis to provide expanded access to additional prophylaxis or to antineoplastic therapy in patients with diffuse large B-cell lymphoma. Read More ›

Page 1 of 7


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: